These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Formulary management of macrolide antibiotics. Guay DR Pharmacoeconomics; 1995 Dec; 8(6):491-512. PubMed ID: 10160079 [TBL] [Abstract][Full Text] [Related]
3. A critical review of the fluoroquinolones: focus on respiratory infections. Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ Drugs; 2002; 62(1):13-59. PubMed ID: 11790155 [TBL] [Abstract][Full Text] [Related]
4. Formulary considerations in selection of beta-blockers. Yedinak KC Pharmacoeconomics; 1993 Aug; 4(2):104-21. PubMed ID: 10150154 [TBL] [Abstract][Full Text] [Related]
5. Gatifloxacin: a review of its use in the management of bacterial infections. Perry CM; Ormrod D; Hurst M; Onrust SV Drugs; 2002; 62(1):169-207. PubMed ID: 11790160 [TBL] [Abstract][Full Text] [Related]
9. Current challenges in the treatment of complicated urinary tract infections and prostatitis. Wagenlehner FM; Naber KG Clin Microbiol Infect; 2006 May; 12 Suppl 3():67-80. PubMed ID: 16669930 [TBL] [Abstract][Full Text] [Related]
10. The fluoroquinolones. Walker RC Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871 [TBL] [Abstract][Full Text] [Related]
11. Quinolones: clinical use and formulary considerations. Cunha BA Adv Ther; 1998; 15(5):277-87. PubMed ID: 10345149 [TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous fluoroquinolones in the treatment of severe infections. Modai J J Chemother; 1999 Dec; 11(6):478-85. PubMed ID: 10678789 [TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method. Janknegt R Pharmacoeconomics; 1994 Jul; 6(1):15-33. PubMed ID: 10147351 [TBL] [Abstract][Full Text] [Related]
14. In vitro antibacterial activity and pharmacodynamics of new quinolones. Dalhoff A; Schmitz FJ Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):203-21. PubMed ID: 12687416 [TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of quinolones in hospitals and the community. Davey P Drugs; 1999; 58 Suppl 2():71-7. PubMed ID: 10553710 [TBL] [Abstract][Full Text] [Related]
16. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. Carson C; Naber KG Drugs; 2004; 64(12):1359-73. PubMed ID: 15200349 [TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Davis R; Markham A; Balfour JA Drugs; 1996 Jun; 51(6):1019-74. PubMed ID: 8736621 [TBL] [Abstract][Full Text] [Related]
18. Maximizing efficacy and reducing the emergence of resistance. Wise R J Antimicrob Chemother; 2003 May; 51 Suppl 1():37-42. PubMed ID: 12702702 [TBL] [Abstract][Full Text] [Related]
19. Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes. Lode HM Int J Antimicrob Agents; 2014 Jun; 43(6):497-507. PubMed ID: 24787481 [TBL] [Abstract][Full Text] [Related]
20. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Croom KF; Goa KL Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]